PHOSPHASAL- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate ta Соединенные Штаты - английский - NLM (National Library of Medicine)

phosphasal- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate ta

biocomp pharma - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - phosphasal ® tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of phosphasal ® tablets has not been reported and due to the nature of its ingredients, abuse of

Hyophen   ™ Соединенные Штаты - английский - NLM (National Library of Medicine)

hyophen ™

biocomp pharma, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), benzoic acid (unii: 8skn0b0mim) (benzoic acid - unii:8skn0b0mim), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - hyophen ® tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of hyophen ® tablets has not been reported and due to the nature of its ingredients, abuse of hyophen ® tablets is not expected.

URIMAR-T- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate tabl Соединенные Штаты - английский - NLM (National Library of Medicine)

urimar-t- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate tabl

scite pharma, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - urimar-t™ is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urimar-t™ is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urimar-t™ has not been reported and due to the nature of its ingredients, abuse of urimar t™ is not expected.

URETRON D/S- methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, and hyoscyamine sulfate tablet Соединенные Штаты - английский - NLM (National Library of Medicine)

uretron d/s- methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, and hyoscyamine sulfate tablet

a.g. marin pharmaceutical - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - uretron d/s tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of uretron d/s tablets has not been reported and due to the nature of its ingredients, abuse of uretron d/s tablets is not expected.

URO-SP- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate capsul Соединенные Штаты - английский - NLM (National Library of Medicine)

uro-sp- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate capsul

scite pharma, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - uro-sp capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uro-sp capsules are contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of uro-sp capsules has not been reported and due to the nature of its ingredients, abuse of uro-sp capsules is not expected.

URNEVA- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, hyoscyamine sulfate capsule Соединенные Штаты - английский - NLM (National Library of Medicine)

urneva- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, hyoscyamine sulfate capsule

scite pharma, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - urneva capsules is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urneva capsules is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urneva capsules has not been reported and due to the nature of its ingredients, abuse of urneva capsules is not expected.

URIMAR-T CAPS- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate Соединенные Штаты - английский - NLM (National Library of Medicine)

urimar-t caps- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate

allegis pharmaceuticals, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - urimar-t™ caps is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urimar-t™ caps is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urimar-t™ caps has not been reported and due to the nature of its ingredients, abuse of urimar t™ caps is not expected.

URIBEL TABS- methenamine, benzoic acid, phenyl salicylate, methylene blue, and hyoscyamine sulfate tablet, coated Соединенные Штаты - английский - NLM (National Library of Medicine)

uribel tabs- methenamine, benzoic acid, phenyl salicylate, methylene blue, and hyoscyamine sulfate tablet, coated

mission pharmacal company - hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), benzoic acid (unii: 8skn0b0mim) (benzoic acid - unii:8skn0b0mim) - uribel tabs are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. a dependence on the use of uribel tabs has not been reported and due to the nature of its ingredients, abuse of uribel tabs is not expected.

SANOS 360 NON SELECTIVE HERBICIDE Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sanos 360 non selective herbicide

sanonda (australia) pty ltd - glyphosate present as the isopropylamine salt - aqueous concentrate - glyphosate present as the isopropylamine salt glycine active 360.0 g/l - herbicide - agricultural area - general | agricultural/farm buildings | avocado, over 3 years old | banana, over 3 years old | citrus over 3 - african boxthorn | african lovegrass | amaranth or amaranthus | annual or wimmera ryegrass | artichoke thistle | bamboo | barley grass | barnyard or water grass | bathurst burr | bent grass - agrostis spp. | bitou bush or boneseed | blackberry | blady grass | bracken | brome grass | brown beetle or silver top grass | bullich | californian thistle | caltrop or yellow vine | camphor laurel | canary grass | capeweed | carpet grass | cat's ear or flatweed | cereal - self-sown | chickweed | chinese scrub | cobbler's pegs | cocksfoot | common reed or phragmites | couch grass | crofton weed | cumbungi | deadnettle | english couch or rope twitch | eucalyptus | flooded gum | fumitory | furze or gorse | ghost gum | glyceria or reed sweet grass | ground or annual ground cherry | groundsel bush | guinea grass | gum topped bloodwood | hawthorn | hedge or wild mustard | hoary cress or whiteweed | jarrah | johnson grass | kangaroo grass | kikuyu grass | lantana - lantana camara | lesser swinecress or bittercress | liverseed